79 results
8-K
EX-99.2
KANT
Kineta, Inc.
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
in immune cell activation and recruitment in the TME Consistent with preclinical models (NHP and KO mice) Biomarker validation of VISTA target
8-K
EX-99.1
KANT
Kineta, Inc.
17 Jan 24
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
8:30am
in immune cell activation and recruitment in the tumor microenvironment (TME).
Pharmacokinetics and Receptor Occupancy (RO)
To guide the recommended
8-K
EX-99.1
KANT
Kineta, Inc.
5 Jan 24
Regulation FD Disclosure
4:30pm
required for strong anti-tumor activity Induces pro-inflammatory myeloid derived cytokines/chemokines involved in immune cell activation and recruitment
424B3
KANT
Kineta, Inc.
13 Nov 23
Prospectus supplement
5:28pm
was observed to induce T cell proliferation and secretion of cytokines involved in T cell priming and recruitment, as well as NK cell activation, suggesting
8-K
EX-99.2
ay2vgot
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
8-K
EX-99.1
i7ar5g lhkj0s5c
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
8-K
EX-99.1
awrvdiwtqm
3 Nov 23
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:02pm
424B5
na830pn uos7rkyf
5 Oct 23
Prospectus supplement for primary offering
10:47am
8-K
EX-99.1
77hurk 1xvy
11 Aug 23
Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:03pm
424B3
4pdowe
12 Jun 23
Prospectus supplement
5:01pm
424B5
1qehxn
21 Apr 23
Prospectus supplement for primary offering
5:14pm
8-K
EX-99.5
e913gq
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.4
11k1o5yg4zomzm 9n
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm